Regular coffee consumption is associated with measurable changes in gut bacteria and lower observed risks of Type 2 diabetes, chronic liver disease, Parkinson’s disease and some cardiovascular conditions, although much of the evidence is observational and does not prove that coffee itself causes those benefits.
By yourNEWS Media Newsroom.
Coffee is among the world’s most widely consumed beverages, and a growing body of research suggests its effects extend well beyond providing a temporary boost in alertness.
Studies have linked regular coffee consumption to changes in the gut microbiome and to lower rates of Type 2 diabetes, chronic liver disease, Parkinson’s disease and certain cardiovascular conditions. Caffeine has also demonstrated short-term performance benefits in controlled exercise studies.
The evidence varies considerably, however. Some findings come from randomized experiments, while many of the strongest associations with chronic disease come from observational studies that cannot establish that coffee itself is responsible for the reduced risk.
A 2026 study published in Nature Communications provided new evidence that coffee can directly alter components of the intestinal microbiome.
Researchers compared 31 habitual coffee drinkers with 31 non-coffee drinkers before asking the coffee-consuming group to abstain for two weeks. Participants were then randomly assigned to drink either caffeinated or decaffeinated coffee for three weeks.
The researchers found changes in specific gut bacterial populations and metabolites as coffee was removed and reintroduced. Importantly, many changes occurred with both caffeinated and decaffeinated coffee, suggesting that substances other than caffeine — including coffee polyphenols — contributed to the response.
The study found that coffee influenced particular microbial strains rather than dramatically changing overall microbial diversity.
Coffee abstinence altered several bacterial species and metabolites, while reintroducing either caffeinated or decaffeinated coffee again shifted microbial composition.
The results provide stronger evidence of an actual coffee-related effect than a simple observational comparison because the researchers followed participants through withdrawal and reintroduction.
They do not establish that those microbiome changes necessarily improve health.
The study also produced mixed findings involving behavior and cognition. Habitual coffee drinkers initially showed greater impulsivity and emotional reactivity than non-drinkers, while different measures of mood, memory, attention and stress changed after coffee withdrawal and reintroduction.
Some improvements occurred with caffeinated coffee and others with decaffeinated coffee.
The authors therefore cautioned against reducing coffee’s effects to a simple conclusion that it is either beneficial or harmful to the brain.
A much larger 2024 investigation similarly found a striking relationship between coffee and intestinal bacteria.
Researchers analyzed detailed dietary information and gut microbiomes from 22,867 people in the United States and United Kingdom before comparing those results with data from tens of thousands of additional participants.
Among approximately 150 foods examined, coffee showed one of the strongest relationships with microbiome composition.
The Nature Microbiology study identified 115 bacterial species positively associated with coffee intake.
One species, Lawsonibacter asaccharolyticus, stood out particularly strongly. Its median abundance was approximately 4.5 to eight times greater in coffee drinkers than in people who did not drink coffee.
Laboratory experiments strengthened the association by showing that coffee could directly stimulate growth of the bacterium.
Researchers also identified coffee-related metabolites associated with both coffee consumption and L. asaccharolyticus.
What those changes mean for human health remains uncertain. Finding more of a particular bacterial species does not by itself establish that the organism is beneficial or that increasing coffee consumption will improve health.
Coffee contains hundreds of biologically active substances.
Among the most studied are chlorogenic acids, a group of polyphenols with antioxidant properties. Coffee also supplies small quantities of riboflavin, pantothenic acid, potassium, manganese and other nutrients.
Caffeine is only one component, which may help explain why several health associations have also been reported with decaffeinated coffee.
That pattern is particularly evident in diabetes research.
A major systematic review and dose-response meta-analysis published in Diabetes Care examined 28 prospective studies involving more than 1.1 million participants.
Compared with people who consumed little or no coffee, those consuming six cups daily had a 33% lower observed risk of developing Type 2 diabetes.
Both caffeinated and decaffeinated coffee were associated with lower risk in the analysis.
The relationship was dose-dependent across the ranges examined, but that does not mean people should begin drinking six cups daily to prevent diabetes.
The study was observational. Coffee drinkers and non-drinkers can differ in diet, activity, socioeconomic factors and other behaviors that are difficult to completely account for.
There is also an apparent contradiction between long-term and short-term research.
Acute caffeine intake can temporarily reduce insulin sensitivity in some experiments, while habitual coffee consumption is consistently associated with a lower long-term incidence of Type 2 diabetes.
That difference suggests that non-caffeine compounds, adaptation to habitual intake or other biological mechanisms may be involved.
Some of coffee’s strongest epidemiological associations involve the liver.
A 2021 UK Biobank study followed nearly 495,000 participants for a median of 10.7 years.
Compared with non-coffee drinkers, coffee consumers had a 21% lower adjusted risk of developing chronic liver disease and a 49% lower risk of dying from chronic liver disease.
The study found similar associations for ground, instant and decaffeinated coffee.
Researchers recorded 3,600 cases of chronic liver disease and 301 deaths from chronic liver disease during follow-up.
Earlier meta-analyses reached similar conclusions.
A 2016 systematic review found that each additional two cups of coffee per day was associated with a 44% lower relative risk of cirrhosis and a 45% lower risk of death from cirrhosis.
The meta-analysis included more than 430,000 participants, although substantial differences existed among the individual studies.
A separate 2017 systematic review involving more than 2.2 million people found that an additional two cups of coffee daily was associated with a 35% lower risk of hepatocellular carcinoma, the most common form of primary liver cancer.
The researchers graded the certainty of that evidence as very low because the underlying studies were observational and subject to potential bias.
That distinction is important: lower disease rates among coffee drinkers do not prove coffee prevents cirrhosis or liver cancer.
Coffee and caffeine have also been studied extensively for their effects on the brain.
Caffeine blocks adenosine receptors, reducing the sensation of fatigue and generally increasing alertness. Controlled experiments have repeatedly found benefits for vigilance, reaction time and attention, particularly when people are tired or sleep-deprived.
Long-term observational research has also identified an association with Parkinson’s disease.
A 2024 study published in Neurology followed participants from six European countries and examined both reported coffee consumption and blood concentrations of caffeine metabolites collected years before Parkinson’s disease developed.
People with the highest coffee consumption had a substantially lower risk of developing Parkinson’s than those who did not drink coffee.
The research was notable because biological markers of caffeine exposure were also associated with subsequent Parkinson’s risk, reducing some of the uncertainty associated with self-reported coffee consumption.
It still did not prove causation.
One biological explanation involves caffeine’s effect on adenosine A2A receptors, which interact with dopamine signaling in brain circuits involved in movement. Those pathways have long attracted research interest because Parkinson’s disease damages dopamine-producing neurons.
Coffee should not, however, be considered a proven preventive treatment for Parkinson’s disease.
Evidence concerning cardiovascular health has also shifted considerably from older warnings that coffee was broadly harmful to the heart.
In July 2026, the American Heart Association published a scientific statement reviewing evidence on caffeine and cardiovascular disease.
The organization concluded that for most healthy adults, up to 400 milligrams of caffeine per day — approximately three to five 8-ounce cups of ordinary caffeinated coffee, depending on strength — is generally considered safe.
The American Heart Association said moderate coffee consumption appears associated with lower risks of several cardiovascular conditions in some populations, including heart disease, heart failure and stroke.
The association does not mean more caffeine is necessarily better.
Large doses, particularly from concentrated energy drinks or energy shots, can raise blood pressure and increase the risk of abnormal heart rhythms in susceptible individuals.
The way coffee is consumed also matters. A cup of black coffee is nutritionally different from a large coffee beverage containing substantial quantities of sugar, flavored syrups or cream.
Caffeine has clearer evidence when the outcome is short-term exercise performance.
A 2022 systematic review and meta-analysis of 21 randomized controlled trials involving 254 participants found that caffeine improved endurance running performance.
Doses in the studies generally ranged from 3 to 9 milligrams per kilogram of body weight.
Caffeine produced a moderate improvement in time-to-exhaustion tests and a smaller but statistically significant improvement in running time trials, according to the analysis.
A separate meta-analysis examining muscle strength and power found small improvements in upper-body strength and muscular power following acute caffeine consumption.
That 2018 review also noted that most participants in the underlying studies were men, limiting how confidently the findings could be generalized to women.
Coffee’s potential benefits therefore depend heavily on the outcome being examined.
For alertness and some exercise measures, caffeine has demonstrated direct effects in controlled trials.
For the gut microbiome, intervention studies now show that coffee can cause measurable changes, although their health implications remain unclear.
For diabetes, Parkinson’s disease, cardiovascular disease, cirrhosis, liver cancer and longevity, most evidence remains observational. Those associations are often consistent across many populations, but they should not be interpreted as proof that drinking coffee will prevent disease.
Coffee can also have disadvantages.
Caffeine can cause nervousness, tremor, palpitations, gastrointestinal discomfort and difficulty sleeping, with sensitivity varying substantially among individuals.
Sleep is among the clearest concerns.
Because caffeine has a relatively long half-life, consuming substantial amounts late in the day can interfere with both sleep onset and sleep quality. Studies have found measurable sleep disruption even when a large caffeine dose is consumed several hours before bedtime.
Pregnant women are generally advised to limit total caffeine consumption to about 200 milligrams per day.
People with certain heart rhythm disorders, uncontrolled hypertension, severe anxiety, reflux or medications that interact with caffeine may also need individualized guidance.
Another consideration is dependence.
Regular caffeine use produces physiological adaptation, and abrupt withdrawal can cause headaches, fatigue, irritability and difficulty concentrating for several days.
Roast level and preparation also affect what ends up in a cup.
Lighter roasting generally preserves more chlorogenic acids, while brewing method influences caffeine and other compounds. Unfiltered coffee, including French press and boiled coffee, can contain higher concentrations of diterpenes such as cafestol and kahweol, which may increase LDL cholesterol in some people.
Coffee beans are also highly variable, meaning “one cup” is not a standardized dose. Caffeine concentrations can differ substantially depending on bean variety, serving size and brewing method.
Taken together, the research presents coffee as a biologically complex beverage rather than simply a caffeine delivery system.
The newest microbiome studies reinforce that distinction: both caffeinated and decaffeinated coffee can produce measurable biological changes.
At the same time, researchers have not established an ideal number of cups that applies to everyone.
For most healthy adults who already enjoy coffee, moderate intake appears compatible with good health and is associated with favorable outcomes in numerous large studies. That evidence does not justify treating coffee as medicine or encouraging people who do not drink it to begin consuming large quantities for disease prevention.
The strongest conclusion from the research is more measured: regular coffee drinking affects human physiology in multiple ways, some of those effects are clearly attributable to caffeine, others appear to involve the beverage’s non-caffeine compounds, and scientists are still working to determine which long-term health associations are truly causal.
Comments